Results 161 to 170 of about 571,282 (185)

Patient-derived glioma organoids real time identification of IDH mutation, 1p/19q-codeletion and CDKN2A/B homozygous deletion with differential ion mobility spectrometry. [PDF]

J Neurooncol
Hermelo I, Haapala I, Mäkelä M, Jacome Sanz D, Kontunen A, Karjalainen M, Müller P, Lehtimäki K, Nykter M, Frösén J, Haapasalo H, Roine A, Oksala N, Nordfors K, Vehkaoja A, Haapasalo J.   +15 more
europepmc   +1 more source

The interplay mechanism between IDH mutation, MGMT-promoter methylation, and PRMT5 activity in the progression of grade 4 astrocytoma: unraveling the complex triad theory. [PDF]

Oncol Res
Kurdi M, Alkhotani A, Sabbagh A, Faizo E, Lary AI, Bamaga AK, Almansouri M, Hafiz B, Alsharif T, Baeesa S.   +9 more
europepmc   +1 more source

Development of End-to-End AI-Based MRI Image Analysis System for Predicting IDH Mutation Status of Patients with Gliomas: Multicentric Validation. [PDF]

J Imaging Inform Med
Santinha J, Katsaros V, Stranjalis G, Liouta E, Boskos C, Matos C, Viegas C, Papanikolaou N.   +7 more
europepmc   +1 more source

Distinguishing IDH mutation status in gliomas using FTIR-ATR spectra of peripheral blood plasma indicating clear traces of protein amyloid aggregation. [PDF]

BMC Cancer
Kino S, Kanamori M, Shimoda Y, Niizuma K, Endo H, Matsuura Y.   +5 more
europepmc   +1 more source

Enhancing predictability of IDH mutation status in glioma patients at initial diagnosis: a comparative analysis of radiomics from MRI, [¹⁸F]FET PET, and TSPO PET. [PDF]

Eur J Nucl Med Mol Imaging
Kaiser L, Quach S, Zounek AJ, Wiestler B, Zatcepin A, Holzgreve A, Bollenbacher A, Bartos LM, Ruf VC, Böning G, Thon N, Herms J, Riemenschneider MJ, Stöcklein S, Brendel M, Rupprecht R, Tonn JC, Bartenstein P, von Baumgarten L, Ziegler S, Albert NL.   +20 more
europepmc   +1 more source

Magnetic Resonance Imaging Derived Biomarkers of IDH Mutation Status and Overall Survival in Grade III Astrocytomas [PDF]

Diagnostics, 2020
The evaluation of the isocitrate dehydrogenase (IDH) mutation status in the glioma decision-making process has diagnostic, prognostic and therapeutic implications. The aim of this study was to evaluate whether conventional magnetic resonance imaging (MRI)
Alessio G Morganti, Paola Feraco, Mattia Barbareschi   +2 more
exaly   +4 more sources

Multicenter DSC–MRI-Based Radiomics Predict IDH Mutation in Gliomas

Cancers, 2021
To address the current lack of dynamic susceptibility contrast magnetic resonance imaging (DSC–MRI)-based radiomics to predict isocitrate dehydrogenase (IDH) mutations in gliomas, we present a multicenter study that featured an independent exploratory ...
Michael Iv, Sotirios Bisdas, Georgios C Manikis   +2 more
exaly   +2 more sources

IDH mutation status and role of WHO grade and mitotic index in overall survival in grade II–III diffuse gliomas [PDF]

Acta Neuropathologica, 2015
Contains fulltext : 153032.pdf (Publisher’s version ) (Closed access)Diffuse gliomas are up till now graded based upon morphology.
Pieter Wesseling, Adriana Olar, Bauke Ylstra   +2 more
exaly   +3 more sources